A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
03 Jun 2013 Final results were presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Peregrine Pharmaceuticals media release.
20 May 2013 Final results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Peregrine media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com